NW-301 TCR-T in Patients With Advanced Solid Tumor

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 10, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Tumor, Solid

Interventions

DRUG

NW-301V

TCR-T T cell targeting KRAS G12V mutation

DRUG

Drug: NW-301D

TCR-T T cell targeting KRAS G12D mutation

Trial Locations (2)

Beijing GoBroad Hospital, Beijing

Peking University Cancer Hospital & Institute, Beijing

All Listed Sponsors

lead

Peking University

OTHER